This is a routine annual meeting filing with no material financial data or guidance. The equity plan approvals are standard governance, monitor for future 10-Q filings to track actual share issuance under the new plans. No immediate trading catalyst.
SRPT drugs
SRPT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $15.75entry
- T+1 · 5mo ago −1.27%α −1.50% · $15.55
- T+5 · 5mo ago −2.79%α −3.36% · $15.31
- T+20 · 4mo ago +21.78%α +19.92% · $19.18
- T+60 · 3mo ago +33.30%α +29.30% · $21.00
Price Chart
How similar events traded
Executive Summary
Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 2026 Equity Incentive Plan (authorizing up to 6,286,841 shares for issuance) and the 2026 Employee Stock Purchase Plan (1,500,000 shares), replacing prior plans. All director nominees were elected, and KPMG was ratified as auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the 2026 Equity Incentive Plan, authorizing up to 6,286,841 shares of common stock for issuance under awards.
- Stockholders approved the 2026 Employee Stock Purchase Plan, authorizing up to 1,500,000 shares of common stock for purchase by employees.
- All five director nominees were elected: Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly.
- Advisory vote on named executive officer compensation for 2025 was approved (45,185,398 For, 22,373,065 Against).
- KPMG LLP was ratified as independent registered public accounting firm for fiscal year ending December 31, 2026 (79,907,368 For, 2,110,136 Against).
- Record date for the meeting was April 8, 2026, with 105,571,146 shares outstanding; 77.97% quorum achieved.
Financial Impact
No financial figures reported. The equity plan authorizes up to 6,286,841 shares (approximately 6.0% of outstanding shares) for future equity compensation, and the ESPP authorizes up to 1,500,000 shares (approximately 1.4% of outstanding) for employee stock purchases at a 15% discount.
Risk Factors
- Potential dilution from future equity awards under the 2026 Plan (up to ~6% of outstanding shares).
- Advisory say-on-pay vote showed 33% opposition (22.4M against), indicating some shareholder dissatisfaction with executive compensation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257501 |
| Document: d88936dex102.htm | 0001193125-26-257501 |
| Document: d88936d8k.htm | 0001193125-26-257501 |
| Document: 0001193125-26-257501-index-headers.html | 0001193125-26-257501 |
| Document: 0001193125-26-257501-index.html | 0001193125-26-257501 |
| Document: 0001193125-26-257501.txt | 0001193125-26-257501 |
Track record
9 reports on SRPT
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $16.07 Now $15.13 −5.85% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.42 Now $15.13 −7.86% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $17.82 Now $15.13 −15.10% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $18.54 Now $15.13 −18.39% settles Dec 2
- Jul 27, 202616w ago 8-K Neutral 3/10 Entry $15.89 to $18.13 Now $15.13 −4.78% ▲ +14.10% +10.80% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $15.00 to $20.52 Now $15.13 +0.87% ▲ +36.80% +34.91% vs SPY
- Jun 4, 202623w ago 8-K Neutral 3/10 Viewing Entry $15.75 to $19.18 Now $15.13 −3.94% ▲ +21.78% +19.92% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $20.89 to $16.67 Now $15.13 −27.56% ▼ −20.18% −25.14% vs SPY
- Feb 25, 202637w ago 8-K Mixed 7/10 Entry $17.45 to $21.68 Now $15.13 −13.30% ▲ +24.24% +30.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers